Ironwood Pharmaceuticals posts Q3 beat and lifts FY2026 revenue and EBITDA outlook
Ironwood Pharmaceuticals reported third‑quarter 2026 revenue of $133.0 million, up 8.9% year‑over‑year, and GAAP net income of $59.8 million, or $0.36 per share. Strong Linzess U.S. sales of $324.9 million, a 3.2% increase, drove the results. The company raised its full‑year 2026 Linzess U.S. net‑sales guidance to $1.20‑$1.25 billion and total revenue guidance to $485‑$510 million, while forecasting adjusted EBITDA above $350 million. It also announced a leadership transition, naming Chief Commercial Officer Tammi Gaskins as President and CEO effective 1 January 2027.
Why it matters
The company expects FY2026 revenue and EBITDA to exceed prior guidance, which could support the stock price and improve cash generation prospects. The leadership change may influence future commercial execution, according to the company’s announcement.
Key facts
- 1Q3 2026 revenue increased 8.9% to $133.0 million. rttnews.com
- 2GAAP net income rose to $59.8 million, or $0.36 per share. rttnews.com
- 3Linzess U.S. net sales were $324.9 million in Q3, up 3.2% YoY. rttnews.com
- 4Adjusted EBITDA reached $97.9 million in Q3. rttnews.com
- 5FY2026 Linzess U.S. net‑sales guidance raised to $1.20‑$1.25 billion. investing.com
- 6FY2026 total revenue guidance lifted to $485‑$510 million. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.